Drug Trial Radar · NCT06743126
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Jan 14, 2025
Primary completion
Jan 2028
Study completion Aug 12, 2032
Sponsor
- Lead sponsor
- Immatics US, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma or mucosal melanoma (MM). For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/
Conditions
- Melanoma, Cutaneous Malignant
- Mucosal Melanoma
Interventions
IMA203Biological
one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy
nivolumab plus relatlimabBiological
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
lifileucelBiological
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
nivolumabBiological
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
pembrolizumabBiological
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
ipilimumabBiological
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
DacarbazineDrug
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
temozolomideDrug
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
paclitaxelDrug
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
paclitaxel plus carboplatinDrug
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Albumin-Bound PaclitaxelDrug
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival assessed by BICRTime frame: up to 5 years post first treatment of last patient
Locations
71 sites in 6 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona · Recruiting
Honor Health Research Institute
Scottsdale, Arizona · Recruiting
City of Hope National Medical Center
Duarte, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
UCLA Hematology/Oncology
Los Angeles, California · Recruiting
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Recruiting
Stanford Cancer Center
Stanford, California · Recruiting
University of Colorado, Anschutz Medical Campus
Aurora, Colorado · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
Mayo Clinic Florida
Jacksonville, Florida · Recruiting
University of Miami - Sylvester Comprehensive Cancer Cente
Miami, Florida · Recruiting
AdventHealth, Orlando
Orlando, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
University of MD Greenebaum Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Atlantic Health System/Morristown Medical Center
Morristown, New Jersey · Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of Rochester
Rochester, New York · Recruiting
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Cleveland Clinic, Taussig Cancer Institute
Cleveland, Ohio · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
Providence Cancer Institute Franz Clinic
Portland, Oregon · Recruiting
Lehigh Valley Topper Cancer Institute
Allentown, Pennsylvania · Recruiting
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania · Recruiting
Thomas Jeffersion University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Avera Cancer Institute
Sioux Falls, South Dakota · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Baylor University
Dallas, Texas · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah · Recruiting
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.